Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Spinal Muscular Atrophy Drugs Development Market Overview
Spinal muscular atrophy (SMA) pipeline market research report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects.
Key Targets in the Spinal Muscular Atrophy (SMA) Pipeline Market
The key targets in the spinal muscular atrophy pipeline market are Survival Motor Neuron Protein, Growth/Differentiation Factor 8, Androgen Receptor, Huntingtin, Potassium Channel Voltage Gated, Chloride Channel Protein 1, Free Radical, and Glycogen Synthase Kinase 3. Survival Motor Neuron Protein has the highest pipeline products.
Spinal Muscular Atrophy (SMA) Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Spinal Muscular Atrophy (SMA) Pipeline Market
The key MoA in the spinal muscular atrophy pipeline market are Survival Motor Neuron Protein Activator, Growth/Differentiation Factor 8 Inhibitor, Androgen Receptor Inhibitor, Potassium Channel Voltage Gated Blocker, Androgen Receptor Antagonist, Chloride Channel Protein 1 Blocker, and Free Radical Scavenger. Survival Motor Neuron Protein Activator has the highest number of pipeline products.
Spinal Muscular Atrophy (SMA) Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Spinal Muscular Atrophy (SMA) Pipeline Market
The key RoA in the spinal muscular atrophy pipeline market are oral, intrathecal, intravenous, subcutaneous, intracerebral, intraocular, and parenteral. Oral has the highest share in the spinal muscular atrophy pipeline market.
Spinal Muscular Atrophy (SMA) Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Spinal Muscular Atrophy (SMA) Pipeline Market
The key molecule types in the spinal muscular atrophy pipeline market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, monoclonal antibody, recombinant protein, antibody, biologic, fusion protein, oligonucleotide, and protein. Small molecule has the highest pipeline products.
Spinal Muscular Atrophy (SMA) Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Spinal Muscular Atrophy (SMA) Pipeline Market
The key companies in the spinal muscular atrophy pipeline market are Biogen Inc, Apteeus SAS, BioMarin Pharmaceutical Inc, F. Hoffmann-La Roche Ltd, Myocea Inc, Novartis Gene Therapies, Oncternal Therapeutics, Alcyone Therapeutics Inc, and AlphaCognition Inc. Biogen Inc has the highest pipeline products.
Spinal Muscular Atrophy (SMA) Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
Key targets | Survival Motor Neuron Protein, Growth/Differentiation Factor 8, Androgen Receptor, Huntingtin, Potassium Channel Voltage Gated, Chloride Channel Protein 1, Free Radical, and Glycogen Synthase Kinase 3 |
Key MoA | Survival Motor Neuron Protein Activator, Growth/Differentiation Factor 8 Inhibitor, Androgen Receptor Inhibitor, Potassium Channel Voltage Gated Blocker, Androgen Receptor Antagonist, Chloride Channel Protein 1 Blocker, and Free Radical Scavenger |
Key RoA | Oral, Intrathecal, Intravenous, Subcutaneous, Intracerebral, Intraocular, and Parenteral |
Key molecule types | Small Molecule, Gene Therapy, Antisense Oligonucleotide, Cell Therapy, Monoclonal Antibody, Recombinant Protein, Antibody, Biologic, Fusion Protein, Oligonucleotide, and Protein |
Key companies | Biogen Inc, Apteeus SAS, BioMarin Pharmaceutical Inc, F. Hoffmann-La Roche Ltd, Myocea Inc, Novartis Gene Therapies, Oncternal Therapeutics, Alcyone Therapeutics Inc, and AlphaCognition Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AlphaCognition Inc
Amniotics AB
Anima Biotech Inc
Annji Pharmaceutical Co Ltd
Apteeus SAS
ARMGO Pharma Inc
Beijing GeneCradle Technology Co Ltd
Biocad
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SA
Cell Tech Pharmed Co
Chugai Pharmaceutical Co Ltd
Enzerna Biosciences LLC
Exegenesis Bio Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
GNT Pharma Co Ltd
Huida (Shanghai) Biotechnology Co Ltd
Imago Pharmaceuticals Inc
Myocea Inc
Neurotune AG
NMD Pharma AS
Novartis AG
Novartis Gene Therapies
Oncternal Therapeutics
Ono Pharmaceutical Co Ltd
PTC Therapeutics Inc
Ractigen Therapeutics Inc
Reborna Biosciences Inc
Sarepta Therapeutics Inc
Scholar Rock Inc
Shift Pharmaceuticals
Spotlight Innovation Inc
Suzhou GenAssist Therapeutics Co Ltd
Voyager Therapeutics Inc
Vybion Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the spinal muscular atrophy (SMA) pipeline market?
The key targets in the spinal muscular atrophy pipeline market are Survival Motor Neuron Protein, Growth/Differentiation Factor 8, Androgen Receptor, Huntingtin, Potassium Channel Voltage Gated, Chloride Channel Protein 1, Free Radical, and Glycogen Synthase Kinase 3.
-
What are the key MoA in the spinal muscular atrophy (SMA) pipeline market?
The key MoA in the spinal muscular atrophy pipeline market are Survival Motor Neuron Protein Activator, Growth/Differentiation Factor 8 Inhibitor, Androgen Receptor Inhibitor, Potassium Channel Voltage Gated Blocker, Androgen Receptor Antagonist, Chloride Channel Protein 1 Blocker, and Free Radical Scavenger.
-
What are the key RoA in the spinal muscular atrophy (SMA) pipeline market?
The key RoA in the spinal muscular atrophy pipeline market are oral, intrathecal, intravenous, subcutaneous, intracerebral, intraocular, and parenteral.
-
What are the key molecule types in the spinal muscular atrophy (SMA) pipeline market?
The key molecule types in the spinal muscular atrophy pipeline market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, monoclonal antibody, recombinant protein, antibody, biologic, fusion protein, oligonucleotide, and protein.
-
What are the key companies in the spinal muscular atrophy (SMA) pipeline market?
The key companies in the spinal muscular atrophy pipeline market are Biogen Inc, Apteeus SAS, BioMarin Pharmaceutical Inc, F. Hoffmann-La Roche Ltd, Myocea Inc, Novartis Gene Therapies, Oncternal Therapeutics, Alcyone Therapeutics Inc, and AlphaCognition Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.